Peptides for Cognitive Enhancement
A mechanism-based review of the most researched nootropic peptides — Semax, Selank, Dihexa, BPC-157, NAD+, and Epithalon — covering evidence levels, comparison data, and PubMed citations.
What Are Nootropic Peptides?
Nootropic peptides are short amino acid chains that cross the blood-brain barrier (BBB) and exert measurable effects on neurological function — including memory, focus, anxiety, and neuroprotection. Unlike classical nootropics (racetams, stimulants), peptides typically work by modulating endogenous neurological pathways rather than directly agonizing receptors, which is associated with a more targeted mechanism and potentially lower side effect profile.
The most studied cognitive peptides fall into three mechanistic categories: those that upregulate neurotrophic factors (BDNF, NGF), those that modulate neurotransmitter systems (dopamine, serotonin, GABA), and those that support neuronal energy metabolism and longevity (NAD+, Epithalon). Several compounds — particularly Semax and Selank — have completed Phase II clinical trials in Russia and are approved prescription medications there, giving them a stronger evidence base than most research peptides.
Key Mechanisms of Action
BDNF & NGF Upregulation
Brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) are the primary drivers of neuroplasticity — the brain's ability to form new synaptic connections. Semax and Selank both significantly upregulate BDNF expression in the hippocampus, the brain region most critical for memory consolidation. Low BDNF is strongly associated with depression, cognitive decline, and Alzheimer's disease.
Synaptogenesis
Dihexa operates through the HGF/c-Met signaling pathway to directly stimulate the formation of new dendritic spines and synaptic connections. In vitro studies show Dihexa is approximately 10 million times more potent than BDNF itself at inducing synaptogenesis — a remarkable finding that has driven significant preclinical interest in cognitive repair applications.
Neurotransmitter Modulation
Several cognitive peptides work by fine-tuning neurotransmitter balance rather than directly stimulating it. Selank modulates GABAergic tone (reducing anxiety without sedation), while BPC-157 has demonstrated the ability to normalize dysregulated dopamine and serotonin systems. This modulatory — rather than agonist — mechanism is associated with a lower side effect profile than classical nootropics.
Neuroprotection & Mitochondrial Support
NAD+ is a critical coenzyme for mitochondrial energy production in neurons. As NAD+ levels decline with age (falling ~50% between ages 40 and 60), neuronal energy metabolism degrades. NAD+ repletion via peptide-adjacent compounds activates sirtuins (SIRT1, SIRT3) and PARP-1, supporting DNA repair and mitochondrial biogenesis — directly addressing the metabolic basis of age-related cognitive decline.
Compound Profiles
Semax
ACTH AnalogueStrongFocus, memory consolidation, neuroprotection
BDNF & NGF upregulation, dopamine/serotonin modulation
Increased BDNF by 80% in rat hippocampus (Dolotov et al., 2006)
~20 min (intranasal)
Intranasal
Selank
Tuftsin AnalogueStrongAnxiety reduction, cognitive clarity, memory
GABAergic modulation, BDNF upregulation, anxiolytic via serotonin/dopamine balance
Reduced anxiety in GAD patients with cognitive improvement (Zozulya et al., 2001)
~2 min (intranasal, active metabolites persist longer)
Intranasal
Dihexa
Angiotensin IV AnaloguePreclinicalCognitive repair, memory, neurogenesis
HGF/c-Met signaling → synaptogenesis, dendritic spine formation
10⁷× more potent than BDNF at inducing synaptogenesis in vitro (McCoy et al., 2013)
Unknown (lipophilic, CNS-penetrant)
Oral / Topical
BPC-157
Gastric PentadecapeptidePreclinicalMood stabilization, dopamine recovery, neuroprotection
Dopamine/serotonin system modulation, VEGF-driven neuroangiogenesis
Reversed dopamine system dysregulation in neuroleptic-treated rats (Sikiric et al., 2014)
Unknown
Subcutaneous / Oral
NAD+
Coenzyme PrecursorModerateBrain energy metabolism, cognitive aging, neuroprotection
Sirtuin activation, mitochondrial biogenesis, DNA repair
NAD+ repletion improved cognitive function in aged mice via SIRT1 activation (Gomes et al., 2013)
~1–2 hrs (IV); variable oral
IV / Subcutaneous / Oral
Epithalon
Pineal TetrapeptidePreclinicalCognitive longevity, sleep-wake cycle, neuroprotection
Telomerase activation, melatonin regulation, antioxidant gene expression
Extended lifespan and improved cognitive function in aged rats (Khavinson et al., 2002)
Unknown
Subcutaneous / IV
Comparison: Cognitive Peptides at a Glance
| Compound | Primary Target | Onset | Cognitive Effect | Anxiety Effect | Human Data |
|---|---|---|---|---|---|
| Semax | BDNF/NGF axis | Minutes (intranasal) | Focus, memory, mood | Mild anxiolytic | Yes (Phase II Russia) |
| Selank | GABAergic / BDNF | Minutes (intranasal) | Clarity, memory | Strong anxiolytic | Yes (Phase II Russia) |
| Dihexa | HGF/c-Met | Hours–days | Synaptogenesis, repair | None reported | No (preclinical only) |
| BPC-157 | Dopamine/serotonin | Days–weeks | Mood, neuroprotection | Mild anxiolytic | Limited |
| NAD+ | Sirtuin / PARP-1 | Days–weeks | Energy, clarity | None direct | Yes (multiple RCTs) |
| Epithalon | Telomerase / melatonin | Weeks | Longevity, sleep | None direct | Limited |
Semax vs. Selank: The Most Researched Cognitive Peptides
Semax and Selank are the two cognitive peptides with the strongest human evidence base. Both were developed by the Institute of Molecular Genetics of the Russian Academy of Sciences and have completed Phase II clinical trials. They are approved prescription medications in Russia for cognitive impairment and anxiety disorders, respectively.
Semax — Focus & Neuroprotection
- → Synthetic ACTH(4-10) analogue with Pro-Gly-Pro extension for stability
- → Upregulates BDNF by ~80% in hippocampus (Dolotov et al., 2006)
- → Enhances dopaminergic and serotonergic neurotransmission
- → Approved in Russia for ischemic stroke and cognitive impairment
- → Administered intranasally; onset within minutes
Selank — Anxiety & Clarity
- → Synthetic analogue of endogenous tuftsin (Thr-Lys-Pro-Arg)
- → Modulates GABAergic tone without benzodiazepine-type sedation
- → Upregulates BDNF; improves memory consolidation
- → Approved in Russia for generalized anxiety disorder
- → Phase II RCT: significant anxiety reduction + cognitive improvement (Zozulya et al., 2001)
Dihexa: Extraordinary Potency, No Human Data
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an angiotensin IV analogue developed at Washington State University. In vitro studies show it is approximately 10 million times more potent than BDNF at inducing synaptogenesis — the formation of new synaptic connections. In aged rat models, oral Dihexa reversed cognitive deficits to a degree comparable to young controls. However, no human clinical trials have been conducted. Its extraordinary potency raises legitimate safety questions about dose-response and long-term effects that remain entirely unstudied in humans.
Key Published Research
Peer-reviewed studies from verified investigators — linked directly to PubMed
Semax, an Analogue of ACTH(4-10) with Cognitive Effects, Regulates BDNF and trkB Expression in the Rat Hippocampus
Dolotov OV, Karpenko EA, Inozemtseva LS, et al.
Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia
Zozulya AA, Neznamov GG, Teleshova ES
Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents
McCoy AT, Benoist CC, Wright JW, et al.
Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging
Gomes AP, Price NL, Ling AJ, et al.
All citations link to verified PubMed records. This site does not fabricate or assign authorship — only real published investigators are listed.
Research-Grade Cognitive Peptides
Purgo Labs offers Selank, Dihexa, NAD+, BPC-157, and Epithalon — all third-party tested for purity and identity. Use code HEALTH for a discount.